Antibacterial compounds
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.
1. A compound having the structure of Formula (II):
or a pharmaceutically acceptable salt, or solvate thereof, wherein,
n is 0-4;
m is 0-4;
A 1 is OH or SH;
A 2 is O or S;
R 1 and R 2 are each independently H or optionally substituted alkyl;
or R 1 and R 2 are taken together with the carbon to which they are attached to form ═C(R 11 ) 2 , ═NR 11 , ═O, or ═S;
or R 1 and R 2 are taken together with the carbon to which they are attached to form an optionally substituted 3- to 6-membered carbocyclyl or optionally substituted 4- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from O, N, and S;
R 3 is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted (C 0 -C 4 alkylene)-COR 11 , optionally substituted (C 0 -C 4 alkylene)-CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-CN, optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—COR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-O—SO 2 N(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 )—PO (optionally substituted C 1 -C 4 alkyl) 2 , optionally substituted (C 0 -C 4 alkylene)-SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-O—SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—SO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-C(═N—OR 11 )(R 11 ), or optionally substituted (C 0 -C 4 alkylene)-OP(═O)(OR 11 ) 2 ;
R 4 is H or optionally substituted alkyl;
or R 3 and R 4 are taken together with the carbon to which they are attached to form ═C(R 11 ) 2 , ═NR 11 , ═O, or ═S;
or R 3 and R 4 are taken together with the carbon to which they are attached to form an optionally substituted 3- to 6-membered carbocyclyl or optionally substituted 4- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from O, N, and S;
R 5 is H, halogen, optionally substituted alkyl, hydroxyl, alkoxyl, cyano, amino, or nitro;
each X and Y is independently H, optionally substituted alkyl, halo, fluoroalkyl, cyano, nitro, —N(R 13 ) 2 , or —OR 13 ;
or R 3 and one X are taken together with the intervening atoms to form an optionally substituted 5- to 7-membered carbocyclyl or optionally substituted 5- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from O, N, and S;
Z is H, halo, nitro, or -L-G;
L is a bond or optionally substituted C 1 -C 4 alkylene;
G is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —CN, —N(R 13 ) 2 , —OR 13 , —COR 13 , —CO 2 R 13 , —CON(R 13 ) 2 , —N(R 14 )—COR 13 , —SO 2 R 13 —, —SO 2 N(R 13 ) 2 , —N(R 14 )—SO 2 R 13 , —N(R 14 )—CON(R 13 ) 2 , —N(R 14 )—CO 2 R 13 , —O—CON(R 13 ) 2 —, —N(R 14 )—SO 2 N(R 13 ) 2 , —O—SO 2 N(R 13 ) 2 , —N(R 14 )—SO 2 —OR 13 , or —C(═N—OR 14 )(R 13 );
each R 11 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl;
or two R 11 on the same nitrogen atom are taken together with the nitrogen to which they are attached to form an optionally substituted N-heterocyclyl;
each R 12 is independently H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
each R 13 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; and
each R 14 is independently H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
wherein
each carbocyclyl is a stable non-aromatic monocyclic, fused polycyclic, or bridged polycyclic hydrocarbon ring comprising from three to ten carbon atoms;
each heterocyclyl is a stable 3- to 18-membered non-aromatic monocyclic, fused bicyclic, bridged bicyclic, or spirocyclic bicyclic ring system comprising from two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur which is optionally oxidized; and
each heterocyclylalkyl is a —R c — heterocyclyl, where R c is a C 1 -C 8 alkylene.
2. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
each X and Y is independently H, optionally substituted alkyl, halo, or cyano.
3. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
each X and Y is independently H, F, or Cl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
n is 0 or 1; and
m is 0 or 1.
5. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
A 1 is OH; and
A 2 is O.
6. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
R 1 is H;
R 2 is H;
R 4 is H; and
R 5 is H.
7. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the structure of Formula (IV):
8. The compound of claim 7 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the structure of Formula (IVa) or Formula (IVb):
9. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
R 3 is optionally substituted alkyl, optionally substituted (C 0 -C 4 alkylene)-CO 2 R 11 , optionally substituted (C 0 -C 4 alkylene)-CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , or optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—SO 2 R 11 .
10. The compound of claim 9 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
R 3 is an unsubstituted alkyl, —CO 2 R 11 , —CON(R 11 ) 2 , optionally substituted (C 0 -C 4 alkylene)-OR 11 , optionally substituted (C 0 -C 4 alkylene)-N(R 11 ) 2 , or optionally substituted (C 0 -C 4 alkylene)-N(R 12 )—SO 2 R 11 .
11. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
each R 11 is H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, or optionally substituted heteroarylalkyl; wherein each R 11 is independently unsubstituted or substituted with halogen, —CN, —R b —OR a , —R b —C(O)R a , or —R b —S(O) y R a ; wherein t is 1 or 2; each R a is independently hydrogen or alkyl which is optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl; and each R b is independently a direct bond or a straight or branched alkylene; or
two R 11 groups are joined with the nitrogen to which they are attached join to form an optionally substituted N-heterocyclyl which is optionally substituted with halogen, oxo, —CN, or —R b —OR a ; wherein each R a is independently hydrogen or alkyl which is optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl; and each R b is independently a direct bond or a straight or branched alkylene; and
each R 12 is independently H or unsubstituted alkyl.
12. The compound of claim 11 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
each R 11 is independently unsubstituted or substituted with —F, —Cl, —CN, —OH, —OMe, —SO 2 Me, or —C(O)Me; or
two R 11 groups are joined with the nitrogen to which they are attached join to form an N-heterocyclyl which is unsubstituted or substituted with —CN, —OH, or —OMe.
13. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
Z is H or -L-G;
L is a bond or optionally substituted C 1 -C 2 alkylene;
G is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , —CN, —COR 13 , —CO 2 R 13 , —CON(R 13 ) 2 , —N(R 14 )—COR 13 , —SO 2 R 13 —, —SO 2 N(R 13 ) 2 , or —N(R 14 )—SO 2 R 13 ; wherein G is unsubstituted or substituted with alkyl, —R b —OR a , —R b —N(R a ) 2 , —R b —C(O)R a , —R b —CN, or —R b —N(R a )C(O)R a ;
each R 13 is independently H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; each of which is independently unsubstituted or substituted with —R b —OR a , —R b —C(O)OR a , or —R b —C(O)R a ;
each R a is independently hydrogen, alkyl which is optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl, or carbocyclyl which is optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl;
each R b is independently a direct bond or a straight or branched alkylene; and
each R 14 is independently H, unsubstituted alkyl, or unsubstituted heterocyclyl.
14. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
Z is -L-G;
L is —CH 2 —;
G is optionally substituted alkyl, optionally substituted heteroaryl, —N(R 13 ) 2 , —OR 13 , —CON(R 13 ) 2 , or —N(R 14 )—COR 13 ; wherein G is unsubstituted or substituted with methyl, —OMe, —CH 2 OH, —NH 2 , —CH 2 NH 2 , —C(O)CH 2 OH, —CN, —CH 2 CN, —CH 2 NHC(O)CH 2 OH;
each R 13 is independently H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; wherein each R 13 is independently unsubstituted or substituted with —OH, —OMe, —C(O)CH 2 OH, —CH 2 C(O)OH, —C(O)OH, —C(O)-cyclopropyl; and
each R 14 is independently H, unsubstituted alkyl, or unsubstituted heterocyclyl.
15. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
G is —N(R 13 ) 2 .
16. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein:
n is 0;
m is 0;
R 3 is
and
Z is
17. The compound of claim 1 , selected from:
or a pharmaceutically acceptable salt, or solvate thereof.
18. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.